Retatrutide — Research Summary
Overview
Retatrutide is an investigational triple hormone receptor agonist that activates receptors for glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and glucagon. This novel research compound represents a new class of multi-receptor agonists being studied for metabolic applications. Retatrutide represents a novel class of multi-receptor agonist peptides that has been the subject of extensive clinical investigation. As a triple agonist simultaneously targeting GIP, GLP-1, and glucagon receptors, it has been studied for its interactions with three distinct but interconnected hormonal signaling pathways involved in glucose homeostasis and energy regulation. The compound's 39-amino acid sequence includes a C20 fatty diacid moiety that has been documented to extend its pharmacokinetic profile. Phase 2 and Phase 3 clinical trials published in peer-reviewed journals including the New England Journal of Medicine and Nature Medicine have examined retatrutide across multiple patient populations and metabolic endpoints. The triple-agonist approach represents an evolution from single-receptor and dual-receptor agonist peptides, and has been the subject of systematic reviews and meta-analyses examining its effects on body weight, glycemic parameters, hepatic fat content, and other metabolic biomarkers.
Compound Profile
The following specifications characterize the Retatrutide research compound as supplied for laboratory investigation purposes.
| Compound Name | Retatrutide |
| Designation | Retatrutide — 10 mg |
| Sequence / Structure | 39-amino acid peptide linked to C20 fatty diacid moiety |
| Purity | ≥99% |
| Form | Lyophilized powder |
| Vial Size | 10mg |
| Storage | Refrigerated after reconstitution |
| Research Category | Metabolic Research |
| Series | Metabolic Series |
| SKU | RT-10 |
Published Research
The following findings have been documented in peer-reviewed publications and scientific literature. These summaries reflect reported observations and are presented for informational purposes in support of laboratory research activities.
- A Phase 2 clinical trial published in the New England Journal of Medicine (Jastreboff et al., 2023) examined retatrutide in adults with obesity over 48 weeks. Researchers observed dose-dependent changes in body weight and metabolic parameters across treatment groups.
- A meta-analysis published in PMC (2024) analyzing three randomized controlled trials encompassing 878 patients reported that retatrutide demonstrated statistically significant effects on body weight, BMI, waist circumference, fasting plasma glucose, and HbA1c compared to placebo.
- Research published in Nature Medicine (2024) examined retatrutide's effects on hepatic fat content in subjects with metabolic dysfunction-associated steatotic liver disease, documenting substantial changes in liver fat measurements at 24 weeks.
- Phase 3 TRIUMPH-4 trial results (December 2025) demonstrated significant improvements in both weight and pain scores in subjects with knee osteoarthritis over 68 weeks of treatment.
These findings reflect outcomes observed in controlled research settings and published study protocols. Individual experimental conditions, model organisms, and methodologies varied across studies. Results observed in preclinical and clinical research settings may not be generalizable.
Mechanism of Action
Triple agonist targeting GIP, GLP-1, and glucagon receptors. Research suggests these pathways are involved in glucose homeostasis, appetite regulation, energy expenditure, and lipid metabolism.
The mechanisms described above have been characterized through published research methodologies including receptor binding assays, gene expression analyses, cell culture experiments, and in vivo preclinical models. Mechanistic understanding continues to evolve as additional research is published.
Research Context
Metabolic pathway research has become one of the most dynamic fields in peptide science, driven by a growing understanding of how hormonal signaling networks regulate energy balance, glucose homeostasis, and lipid metabolism. Investigators have examined a range of peptide compounds that interact with receptors involved in appetite regulation, insulin sensitivity, and metabolic rate. The study of incretin receptor agonists and multi-receptor agonists has attracted significant attention from the research community, with large-scale clinical trials documenting their effects on metabolic parameters. Research in this area employs diverse methodologies, from in vitro receptor binding assays to randomized controlled trials with comprehensive metabolic biomarker panels. The interaction between metabolic peptides and pathways such as GLP-1, GIP, and glucagon receptor signaling continues to be a major focus of published investigations.
Retatrutide has been studied within this broader research context. The compound is classified under the Metabolic Research category and is part of the Metabolic Series in the Hot Peps research catalog. Researchers investigating metabolic research may find the published findings summarized above relevant to their experimental design and literature review processes.
Key Citations
The following references represent a selection of published studies relevant to Retatrutide research. Full-text articles may be accessed through their respective journal publishers or indexed databases such as PubMed.
- Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389:514-526.PMID: 37366315
- Efficacy and safety of retatrutide for obesity treatment: systematic review and meta-analysis.PMID: PMC12026077
- Nature Medicine. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease. 2024. doi:10.1038/s41591-024-03018-2
This compound is part of the Metabolic Stack — appetite + metabolic signaling focus.
View Kit →Important Notice
Retatrutide is sold exclusively for in vitro research, laboratory use, and scientific investigation purposes. This compound is not intended for human consumption, veterinary use, or any therapeutic application. It is not intended to diagnose, treat, cure, or prevent any disease or medical condition.
All research findings, statistics, and outcomes referenced on this page have been sourced from published peer-reviewed studies and scientific literature. These summaries are provided for informational purposes to support qualified researchers in their laboratory investigations. Results documented in published research were obtained under specific experimental conditions and may not be reproducible in all settings.
Researchers are responsible for ensuring that their use of research compounds complies with all applicable local, state, and federal regulations governing laboratory research materials.
Related Research Insights
Explore the Complete Guide to Research Peptides →Learn More About Peptide Research
All findings referenced on this page reflect outcomes reported in published research studies. This product is sold strictly for in vitro research, laboratory use, and scientific investigation only. Not for human or veterinary use. Not intended to diagnose, treat, cure, or prevent any disease.